FOI 5687-Cancer treatments for patients

Date: 25 September 2019 to 25 September 2022

1 - In the past 3 months, how many  Squamous Cell Non-small cell lung cancer (SqNSCLC) patients were treated with:

Afatinib

Atezolizumab monotherapy

Bevacizumab

Docetaxel monotherapy

Durvalumab

Erlotinib

Gemcitabine

Necitumumab

Nivolumab

Paclitaxel

Pembrolizumab monotherapy

Pembrolizumab chemo in combination

Pemetrexed

Ramucirumab

Vinorelbine and cisplatin / carboplatin

Other active systemic anti-cancer therapy [please state]

Palliative care only

 

2 - In the past 3 months, how many Non Squamous Cell Non-small cell lung cancer (Non SqNSCLC) patients were treated with:

Afatinib

Alectinib

Atezolizumab mono

Atezolizumab + bevacizumab + carboplatin + paclitaxel

Bevacizumab

Brigatinib

Ceritinib

Crizotinib

Dacomitinib

Docetaxel monotherapy

Erlotinib

Gefitinib

Nintedanib with docetaxel

Nivolumab

Osimertinib

Paclitaxel

Pembrolizumab monotherapy

Pembrolizumab chemo in combination

Pemetrexed with carboplatin

Pemetrexed with cisplatin

Ramucirumab

Other active systemic anti-cancer therapy [please state]

Palliative care only

 

3 - In the past 3 months, how many Urothelial cancer patients were treated with;

Atezolizumab

Carboplatinum in combination with another agent

Carboplatinum single agent

Cisplatinum in combination with another agent

Cisplatinum single agent

Nivolumab

Pembrolizumab 

Any other chemo regimen without cisplatinum or carboplatinum

Other active systemic anti-cancer therapy [please state]

Palliative care only

  • Request ID:
    FOI 5687
  • Category:
    Clinical - Drugs
  • Response:

    1 - In the past 3 months, how many  Squamous Cell Non-small cell lung cancer (SqNSCLC) patients were treated with:

    Afatinib

    Atezolizumab monotherapy

    Bevacizumab

    Docetaxel monotherapy

    Durvalumab

    Erlotinib

    Gemcitabine

    Necitumumab

    Nivolumab

    Paclitaxel

    Pembrolizumab monotherapy

    Pembrolizumab chemo in combination

    Pemetrexed

    Ramucirumab

    Vinorelbine and cisplatin / carboplatin

    Other active systemic anti-cancer therapy [please state]

    Palliative care only

    Medway NHS Foundation Trust regret that we are unable to answer your request as this data is not collated.  However, the Trust’s Pharmacy Department can provide the number of patients that have been dispensed each drug, but are unable to provide the indication that the drug was prescribed for as this data is not held against pharmacy records.  Please find attached for your information.

     

    2 - In the past 3 months, how many Non Squamous Cell Non-small cell lung cancer (Non SqNSCLC) patients were treated with:

    Afatinib

    Alectinib

    Atezolizumab mono

    Atezolizumab + bevacizumab + carboplatin + paclitaxel

    Bevacizumab

    Brigatinib

    Ceritinib

    Crizotinib

    Dacomitinib

    Docetaxel monotherapy

    Erlotinib

    Gefitinib

    Nintedanib with docetaxel

    Nivolumab

    Osimertinib

    Paclitaxel

    Pembrolizumab monotherapy

    Pembrolizumab chemo in combination

    Pemetrexed with carboplatin

    Pemetrexed with cisplatin

    Ramucirumab

    Other active systemic anti-cancer therapy [please state]

    Palliative care only

    Please see question 1 above.

     

    3 - In the past 3 months, how many Urothelial cancer patients were treated with;

    Atezolizumab

    Carboplatinum in combination with another agent

    Carboplatinum single agent

    Cisplatinum in combination with another agent

    Cisplatinum single agent

    Nivolumab

    Pembrolizumab 

    Any other chemo regimen without cisplatinum or carboplatinum

    Other active systemic anti-cancer therapy [please state]

    Palliative care only

    Please see question 1 above.